6090 Stock Overview
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Human Metabolome Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥662.00 |
| 52 Week High | JP¥794.00 |
| 52 Week Low | JP¥588.00 |
| Beta | 0.60 |
| 1 Month Change | 2.95% |
| 3 Month Change | 0.15% |
| 1 Year Change | -6.63% |
| 3 Year Change | -23.64% |
| 5 Year Change | -26.93% |
| Change since IPO | -76.71% |
Recent News & Updates
Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year
Apr 06
Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Mar 23Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00
Feb 26Shareholder Returns
| 6090 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -2.9% | 1.0% | 1.8% |
| 1Y | -6.6% | -34.1% | 31.0% |
Return vs Industry: 6090 exceeded the JP Life Sciences industry which returned -34.1% over the past year.
Return vs Market: 6090 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 6090 volatility | |
|---|---|
| 6090 Average Weekly Movement | 2.4% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 6090 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6090's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 57 | Katsuhito Hashizume | www.humanmetabolome.com |
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma.
Human Metabolome Technologies, Inc. Fundamentals Summary
| 6090 fundamental statistics | |
|---|---|
| Market cap | JP¥3.92b |
| Earnings (TTM) | JP¥282.00m |
| Revenue (TTM) | JP¥1.32b |
13.9x
P/E Ratio3.0x
P/S RatioIs 6090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6090 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.32b |
| Cost of Revenue | JP¥462.00m |
| Gross Profit | JP¥859.00m |
| Other Expenses | JP¥577.00m |
| Earnings | JP¥282.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 47.67 |
| Gross Margin | 65.03% |
| Net Profit Margin | 21.35% |
| Debt/Equity Ratio | 11.3% |
How did 6090 perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield21%
Payout RatioDoes 6090 pay a reliable dividends?
See 6090 dividend history and benchmarks| Human Metabolome Technologies dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2024 |
| Dividend Pay Date | Sep 09 2024 |
| Days until Ex dividend | 62 days |
| Days until Dividend pay date | 136 days |
Does 6090 pay a reliable dividends?
See 6090 dividend history and benchmarks